Abstract:Guoquan Chen, 1, &ast Jiale Chen, 1, &ast Qiang Zhao, 2 Yalan Zhu 1 1 Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China; 2 Department of Cardiology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yalan Zhu, Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China, Tel +86-0579-82552760, Email Objective: Atrial fibrillation (AF) is the most common abnormal heart rhythm in elderly patients. Rivaroxaban has been widely used for stroke prevention. The anticoagulant response to rivaroxaban increases with age, which may make elderly patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Methods: We designed a cohort study of ≥ 65-year-old inpatients with AF. Sociodemographic and laboratory measures of qualified patients who received brand or generic rivaroxaban for at least 72 hours at the study hospital from January 2021 to June 2023 were collected retrospectively. The primary outcome was the incidence of bleeding. Results: A total of 1008 qualifying patients were included for analysis, with 626 (62.1%) receiving brand rivaroxaban and 382 (37.9%) receiving generic rivaroxaban. After propensity score matching and weighting to account for confounders, the odds ratios comparing brand vs generic rivaroxaban (95% confidence intervals) for the bleeding was 1.15 (0.72– 1.82). Results from subgroup analyses of patients with age ≥ 85, HAS-BLED score ≥ 3, containment of antiplatelet drugs, and female patients were consistent with the primary analysis. Conclusion: It provides evidence regarding the clinical safety outcome of generic rivaroxaban in the elderly AF population that may be particularly susceptible to adverse outcomes resulting from small allowable differences in pharmacokinetics. Keywords: bleeding, rivaroxaban, generic, brand, atrial fibrillation Generic medicine contains the same active substance(s) as brand/reference medicine and is bioequivalent to brand/reference medicine. Generally, generic medicine 1 is considered to be comparable to brand/reference medicine in dosage form, route of administration, and treatment characteristics. In the context of increasing global healthcare expenditure, generic medicine utilization is often encouraged as a cost-containment measure, which can be priced as low as 2–10% of pre-patent loss prices. 2 While the negative opinions about generic medicines by both professionals and the general public interfere with the acceptance of generic medicines in healthcare provision. 3 Atrial fibrillation (AF) is one of the most common cardiac arrhythmias in elderly patients. 4 Rational anticoagulation for stroke prevention is one of the pillars of AF management. 5 Direct oral anticoagulants (DOACs) are now recommended as first-line therapy by up-to-date guidelines. 6,7 Rivaroxaban 8 is a direct factor Xa inhibitor, targeting free and clot-bound coagulation factor Xa and blocking the common coagulation pathway. Despite a better safety profile than warfarin, 9 as more patients are being treated with rivaroxaban, the absolute number of bleeding events increases. 10 Advanced age 11 is a shared risk factor for both thromboembolic and bleeding events. Additionally, elderly patients frequently face challenges such as polypharmacy, poor medication adherence, impaired liver and kidney function, and increased risk of falls and undernutrition, 12–14 which make them more susceptible to suboptimal anticoagulation or excessive anticoagulation when receiving rivaroxaban treatment. Elderly subjects exhibited higher plasma concentrations, with mean AUC values being 41% higher in the elderly than in younger subjects. 15 When formulating an individualized anticoagulation regimen for elderly patients with AF, the consistency of safety and efficacy between brand and generic rivaroxaban has been a main clinical concern. Given the wide use of rivaroxaban, it is important to assess whether small allowable differences in bioavailability between brand and generic versions are associated with differences in clinical outcomes in the real world. Currently, no studies have been conducted to compare the clinical outcomes between generic and brand rivaroxaban. To that end, we designed this study of 65 years or older inpatients with AF to compare clinical -Abstract Truncated-

Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria

Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses

Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study

A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study.

Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials

A systematic review and meta-analysis of the morbidity of efficacy endpoints and bleeding events in elderly and young patients treated with the same dose rivaroxaban

Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants

Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis.

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk

Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis

Bleeding Risks with Novel Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation: a Systematic Review and Network Meta-Analysis.

Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation

Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation

Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation

Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin among Nursing Home Residents with Atrial Fibrillation: A Retrospective Cohort Study

Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation